<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02413606</url>
  </required_header>
  <id_info>
    <org_study_id>IKZ 2014-6677</org_study_id>
    <nct_id>NCT02413606</nct_id>
  </id_info>
  <brief_title>ENdometrial Cancer SURvivors' Follow-up carE (ENSURE): Less is More?</brief_title>
  <acronym>ENSURE</acronym>
  <official_title>ENdometrial Cancer SURvivors' Follow-up carE (ENSURE): Less is More? Randomized Controlled Trial to Evaluate Patient Satisfaction and Cost-effectiveness of a Reduced Follow-up Schedule</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Comprehensive Cancer Centre The Netherlands</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Dutch Cancer Society</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Maastricht University Medical Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Leiden University Medical Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Comprehensive Cancer Centre The Netherlands</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Background: It has often been hypothesized that the frequency of follow-up for patients with
      early-stage endometrial cancer could be decreased. However, studies evaluating effects of a
      reduced follow-up schedule among this patient group are lacking.

      Objective: Assess patient satisfaction and cost-effectiveness of a less frequent follow-up
      schedule compared to the schedule according to the Dutch guideline.

      Study design: Dutch multicentre randomized controlled trial with a 5 year follow-up. Patients
      (n=282) are randomized in an intervention group with 4 follow-up visits during 3 years, and a
      control group with 10-13 follow-up visits during 5 years, according to the Dutch guideline.
      Patients are asked to fill out a questionnaire at baseline, 6, 12, 36 and 60 months. Patient
      inclusion will take two years (if 60% of the patients participate).

      Outcomes: Primary: Patient satisfaction with follow-up care and cost-effectiveness.

      Secondary: health care use, adherence to schedule, health-related quality of life, fear of
      recurrence, anxiety and depression, information provision, recurrence, survival

      Patients: Stage 1A and 1B low-risk endometrial cancer patients, for whom adjuvant
      radiotherapy is not indicated

      Statistics: linear regression analyses to assess differences in patient satisfaction with
      follow-up care between intervention and control group adjusted for potential pre-defined
      confounders.

      Expected results: Patients in the intervention arm have a similar satisfaction with follow-up
      care and overall outcomes, but lower health care use and costs than patients in the control
      arm. No effects are expected on QALY differences (losses) and satisfaction, but the reduced
      schedule is expected to save 144.000 per year in the Netherlands.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 2015</start_date>
  <completion_date type="Anticipated">December 2022</completion_date>
  <primary_completion_date type="Anticipated">December 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Health Services Research</primary_purpose>
    <masking>Single (Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Patient satisfaction with follow-up care</measure>
    <time_frame>up to 60 months after completion of primary treatment</time_frame>
    <description>assessed with the PSQIII questionnaire; analysed with a repeated mixed model as one overall outcome over all time points</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Costs-effectiveness</measure>
    <time_frame>assessed at 60 months after completion of primary treatment</time_frame>
    <description>Cost-effectiveness from the health care perspective using the EQ-5D</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Costs-effectiveness</measure>
    <time_frame>assessed at 36 months after completion of primary treatment</time_frame>
    <description>Cost-effectiveness from the health care perspective using the EQ-5D</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Health care use -gynaecologist, (specialist) nurse, primary care physician and other health or care services-; adherence to the indicated follow-up protocols; reasons for non-adherence</measure>
    <time_frame>assessed at 6, 12 and 36 months after completion of primary treatment</time_frame>
    <description>health care use is assessed from hospital charges, primary care physician and self-report; analysed with a repeated mixed model as one overall outcome over all time points</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Health care use -gynaecologist, (specialist) nurse, primary care physician and other health or care services-; adherence to the indicated follow-up protocols; reasons for non-adherence</measure>
    <time_frame>assessed at 6, 12, 36, and 60 months after completion of primary treatment</time_frame>
    <description>health care use is assessed from hospital charges, primary care physician and self-report; analysed with a repeated mixed model as one overall outcome over all time points</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Health-Related Quality of Live</measure>
    <time_frame>assessed at baseline, 6, 12, and 36 months after completion of primary treatment</time_frame>
    <description>assessed with questionnaires: EORTC QLQ-C30 and EORTC QLQ-EN24; analysed with a repeated mixed model as one overall outcome over all time points</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Health-Related Quality of Live</measure>
    <time_frame>assessed at baseline, 6, 12, 36, and 60 months after completion of primary treatment</time_frame>
    <description>assessed with questionnaires: EORTC QLQ-C30 and EORTC QLQ-EN24; analysed with a repeated mixed model as one overall outcome over all time points</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Worry including fear of recurrence</measure>
    <time_frame>assessed at baseline, 6, 12, and 36 months after completion of primary treatment</time_frame>
    <description>assessed with questionnaire: IOCv2; analysed with a repeated mixed model as one overall outcome over all time points</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Worry including fear of recurrence</measure>
    <time_frame>assessed at baseline, 6, 12, 36, and 60 months after completion of primary treatment</time_frame>
    <description>assessed with questionnaire: IOCv2; analysed with a repeated mixed model as one overall outcome over all time points</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Illness perceptions</measure>
    <time_frame>assessed at baseline, 6, 12, and 36 months after completion of primary treatment</time_frame>
    <description>assessed with questionnaire: BIPQ; analysed with a repeated mixed model as one overall outcome over all time points</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Illness perceptions</measure>
    <time_frame>assessed at baseline, 6, 12, 36, and 60 months after completion of primary treatment</time_frame>
    <description>assessed with questionnaire: BIPQ; analysed with a repeated mixed model as one overall outcome over all time points</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Anxiety and depression</measure>
    <time_frame>assessed at baseline, 6, 12, and 36 months after completion of primary treatment</time_frame>
    <description>assessed with questionnaire: HADS; analysed with a repeated mixed model as one overall outcome over all time points</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Anxiety and depression</measure>
    <time_frame>assessed at baseline, 6, 12, 36, and 60 months after completion of primary treatment</time_frame>
    <description>assessed with questionnaire: HADS; analysed with a repeated mixed model as one overall outcome over all time points</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Satisfaction with information provision</measure>
    <time_frame>assessed at baseline, 6, 12, and 36 months after completion of primary treatment</time_frame>
    <description>assessed with questionnaire: EORTC-INFO25; analysed with a repeated mixed model as one overall outcome over all time points</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Satisfaction with information provision</measure>
    <time_frame>assessed at baseline, 6, 12, 36, and 60 months after completion of primary treatment</time_frame>
    <description>assessed with questionnaire: EORTC-INFO25; analysed with a repeated mixed model as one overall outcome over all time points</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Health care providers' satisfaction with follow-up schedule (gynaecologist, (specialised) nurse)</measure>
    <time_frame>assessed at 36 months after completion of primary treatment</time_frame>
    <description>assessed with structured interviews/questionnaires</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Health care providers' satisfaction with follow-up schedule (gynaecologist, (specialised) nurse)</measure>
    <time_frame>assessed at 60 months after completion of primary treatment</time_frame>
    <description>assessed with structured interviews/questionnaires</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time till recurrence</measure>
    <time_frame>assessed at 36 months after completion of primary treatment</time_frame>
    <description>In this study we will descriptively look at time till recurrence</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time till recurrence</measure>
    <time_frame>assessed at 60 months after completion of primary treatment</time_frame>
    <description>In this study we will descriptively look at time till recurrence</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Survival</measure>
    <time_frame>assessed at 36 months after completion of primary treatment</time_frame>
    <description>descriptively look at survival</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Survival</measure>
    <time_frame>assessed at 60 months after completion of primary treatment</time_frame>
    <description>descriptively look at survival</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">282</enrollment>
  <condition>Endometrial Cancer</condition>
  <arm_group>
    <arm_group_label>Intervention</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>reduced follow-up schedule: 4 follow-up visits, after 3, 12, 24 and 36 months</description>
  </arm_group>
  <arm_group>
    <arm_group_label>control</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>regular follow-up schedule according to the guideline, 10-13 visits during 5 years</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Reduced follow-up schedule</intervention_name>
    <description>In the intervention group, the follow-up schedule will be limited to four follow-up visits at 3, 12, 24 and 36 months, under the specific condition that patients have easy and prompt access to care (specialised nurse of gynaecologist) if symptoms or questions occur. The content of the follow-up visits will be similar for both groups.</description>
    <arm_group_label>Intervention</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Patients with Endometrio√Ød type endometrial carcinoma with stage 1 (FIGO, 2009)
             disease, with the following combination of stage, age and grade:

             Stage 1A, any age, grade 1 or 2; Stage 1B, &lt; 60 years, grade 1 or 2 without LVSI;

          2. Written informed consent;

          3. Sufficient oral and written command of the Dutch language.

        Exclusion Criteria:

          1. Any other stage and type of endometrial carcinoma

          2. Histological types papillary serous carcinoma or clear cell carcinoma

          3. Uterine sarcoma (including carcinosarcoma)

          4. Radiotherapy for current endometrial carcinoma

          5. Previous malignancy (except for non-melanomatous skin cancer) &lt; 5 yrs

          6. Confirmed Lynch syndrome

          7. Previous pelvic radiotherapy
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Lonneke van de Poll-Franse, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Comprehensive Cancer Centre The Netherlands</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Roy Kruitwagen, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Maastricht University Medical Centre</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Carien Creutzberg, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Leiden University Medical Centre</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Nicole Ezendam, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Comprehensive Cancer Centre The Netherlands</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Nicole Ezendam, PhD</last_name>
    <phone>+31 88 2346096</phone>
    <email>n.ezendam@iknl.nl</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Lonneke van de Poll-Franse, PhD</last_name>
    <phone>+31 88 2346273</phone>
    <email>l.vandepoll@iknl.nl</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Meander Medisch Centrum</name>
      <address>
        <city>Amersfoort</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Amstelland Ziekenuis</name>
      <address>
        <city>Amstelveen</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>AMC</name>
      <address>
        <city>Amsterdam</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>AVL</name>
      <address>
        <city>Amsterdam</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>OLVG</name>
      <address>
        <city>Amsterdam</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Brenda Hermsen</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Gelre Ziekenhuizen</name>
      <address>
        <city>Apeldoorn</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Bravis</name>
      <address>
        <city>Bergen op Zoom</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Tergooi</name>
      <address>
        <city>Blaricum</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Amphia</name>
      <address>
        <city>Breda</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Reinier de Graaf Hospital</name>
      <address>
        <city>Delft</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Jeroen Bosch</name>
      <address>
        <city>Den Bosch</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Haga hospital</name>
      <address>
        <city>Den Haag</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>MC Haaglanden</name>
      <address>
        <city>Den Haag</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Deventer Hospital</name>
      <address>
        <city>Deventer</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Catharina Hospital</name>
      <address>
        <city>Eindhoven</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Medical Spectrum Twente</name>
      <address>
        <city>Enschede</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Groene Hart</name>
      <address>
        <city>Gouda</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Martini Hospital</name>
      <address>
        <city>Groningen</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>UMC Groningen</name>
      <address>
        <city>Groningen</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Zuyderland Hospital</name>
      <address>
        <city>Heerlerheide</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Westfries Gasthuis</name>
      <address>
        <city>Hoorn</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Medical Center Leeuwarden</name>
      <address>
        <city>Leeuwarden</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mirjam Apperloo</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Alrijne Ziekenhuis</name>
      <address>
        <city>Leiden</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Leiden University Medical Center</name>
      <address>
        <city>Leiden</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Maastricht University Medical Center</name>
      <address>
        <city>Maastricht</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Roy Kruitwagen</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Waterland Ziekenhuis</name>
      <address>
        <city>Purmerend</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Bravis</name>
      <address>
        <city>Roosendaal</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Franciscus Gasthuis</name>
      <address>
        <city>Rotterdam</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Vlietland</name>
      <address>
        <city>Schiedam</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Zuyderland</name>
      <address>
        <city>Sittard</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Elisabeth TweeSteden, TweeSteden</name>
      <address>
        <city>Tilburg</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Elisabeth-TweeSteden</name>
      <address>
        <city>Tilburg</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Bernhoven</name>
      <address>
        <city>Uden</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Maxima Medisch Centrum</name>
      <address>
        <city>Veldhoven</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>VieCuri</name>
      <address>
        <city>Vennen</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Zuwe Hofpoort</name>
      <address>
        <city>Woerden</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Zaans Medisch Centrum</name>
      <address>
        <city>Zaandam</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>M Verbruggen</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Langeland</name>
      <address>
        <city>Zoetermeer</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Gelre Ziekenhuizen</name>
      <address>
        <city>Zutphen</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Isala kliniek</name>
      <address>
        <city>Zwolle</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Netherlands</country>
  </location_countries>
  <verification_date>January 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 24, 2015</study_first_submitted>
  <study_first_submitted_qc>April 9, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 10, 2015</study_first_posted>
  <last_update_submitted>January 30, 2017</last_update_submitted>
  <last_update_submitted_qc>January 30, 2017</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 31, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Comprehensive Cancer Centre The Netherlands</investigator_affiliation>
    <investigator_full_name>Nicole Ezendam</investigator_full_name>
    <investigator_title>Dr.</investigator_title>
  </responsible_party>
  <keyword>follow up care</keyword>
  <keyword>satisfaction with care</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Endometrial Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>After ending the study and analysis of the data, data becomes available for use by other researchers via PROFILES registry, according to the their terms</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

